Alzheimer's blood test predicts cognitive decline risk in older adults
Key Points:
- A Mayo Clinic study published in JAMA Neurology found that a blood test measuring phosphorylated tau 217 (p-tau217) protein can help predict the risk of cognitive decline in older adults within five to 10 years.
- The study involved 2,178 cognitively unimpaired adults aged 60 to 90 and accounted for factors like age, gender, and the APOE ε4 genetic variant linked to Alzheimer's risk.
- Older age was strongly associated with higher risk of mild cognitive impairment at the same p-tau217 levels, with an 85-year-old facing a 37% five-year risk compared to 6% for a 65-year-old.
- The blood test offers a less invasive and potentially more scalable alternative to PET scans for detecting Alzheimer’s pathology, but it is not yet ready for routine screening as no preventive treatments are currently approved for asymptomatic individuals.
- Researchers emphasize that the findings need replication in more diverse populations and that having Alzheimer’s pathology does not guarantee cognitive decline, as some individuals may never develop symptoms in their lifetime.